Exploiting common genetic variation to make anticoagulation safer

Stroke. 2009 Mar;40(3 Suppl):S64-6. doi: 10.1161/STROKEAHA.108.533190. Epub 2009 Jan 15.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Aging / genetics
  • Anticoagulants / adverse effects*
  • Aryl Hydrocarbon Hydroxylases / genetics
  • Blood Coagulation / genetics*
  • Cytochrome P-450 CYP2C9
  • Female
  • Genetic Variation / genetics*
  • Humans
  • Intracranial Hemorrhages / epidemiology
  • Intracranial Hemorrhages / prevention & control
  • Male
  • Mixed Function Oxygenases / genetics
  • Risk Factors
  • Vitamin K Epoxide Reductases
  • Warfarin / adverse effects

Substances

  • Anticoagulants
  • Warfarin
  • Mixed Function Oxygenases
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Vitamin K Epoxide Reductases